Peg Grafeel 6 mg Injection contains Pegfilgrastim, a long-acting colony-stimulating factor (G-CSF) formulation. It is indicated to reduce the duration of neutropenia and lower the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies.
Pegfilgrastim works by stimulating the bone marrow to produce white blood cells (neutrophils), which are critical for fighting bacterial infections during cancer chemotherapy. The pegylated formulation allows for convenient single-dosing per chemotherapy cycle.
It is administered as a subcutaneous injection, typically 24 hours after a chemotherapy dose. It must be stored under refrigeration (2°C–8°C) and protected from light.
Before therapy, inform your oncologist of any history of sickle cell anaemia, spleen disorders, or kidney problems. Regular complete blood counts (CBC) are performed to monitor neutrophil recovery.













































